Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.
The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.
Hires and promotions for manufacturers, regulatory and agencies
Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.
The plan is to bring in-house products to the market as well as through acquisitions.
The $225-million deal will give Mylan one of two generics for the deep vein thrombosis drug.
The Milbank Quarterly has published a study that may put Sunshine skeptics on edge.
The impact health monitors have on consumer habits and on patient-physician relationships has yet to be quantified.
A US investigation into GlaxoSmithKline has stirred up internal paperwork that the UK drugmaker was looking into compliance violations in its consumer division in 2012.
The London healthcare brand and research agency will be part of Omnicom's DAS Group.
The new site, which includes professional resources on diabetes, debuted online and in app form today.
The media company has added managed-markets expertise to its roster, bringing on the former head of IMS Health's global payer/provider division.
Manufacturer, agency and consulting hires and promotions
The latest data shows an overall widening of the US.
Bloomberg reports that India's Wockhardt has become an M&A target.
Pfizer will sell two Novartis drugs in the UK.
Parent company CVS Caremark is changing its name to better reflect "its broader health care commitment."
Sales reps are among the pinked-slipped in Spain.
The FDA froze the clinical trial of anti-Fzd7 vantictumab in July over concern about "bone-related adverse events."
Baylor College of Medicine researchers have found that an estrogen replacement suppressed binge-eating behavior among lab mice.
Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.
Illinois may be tempted to offer tax incentives for the firm to stay put.
FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.
The $300,000 grant will go towards an abuse-deterrent technology.
A study of psoriatic arthritis patients found greater adherence among patients whose initial treatment was a biologic, compared to those who started with a non-biologic treatment.
A Treasury report says the IRS is having trouble identifying who owes it money.
A proposal by the Obama administration Friday seeks to keep contraception accessible and coverage approval at arm's length for employees of religious non-profits.
Diet and exercise can help some type-2 diabetes patients save around $500 in medical expenses every year.
J&J subsidiary Janssen has abandoned its patent lawsuit over the anti-seizure medication topiramate, which is part of Vivus's prescription weight-loss drug Qsymia.
Manufacturer and Agency hires and promotions
The goal is to develop companion diagnostics to match patients with cancer treatments.
Political furor over the recent spate of tax inversions is having little influence on how the government chooses its partners.
The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.
Inspectors of Marck Biosciences found an array of problems during a October-November 2013 inspection, including mold near a sterile area that was so bad "the room had 'partially caved in.'"
AstraZeneca announced the end of the investigation Tuesday.
A host of doctors has asked FDA Commissioner Margaret Hamburg to back a naming convention that would require biologics and biosimilars to have different names.
Despite a collaboration with original Sovaldi owner Pharmasset in 2004, a panel ruled Roche has no rights to HCV treatment Sovaldi.
The Japanese drugmaker is looking to add as much as a year onto the patent life of some of its drugs after the DEA dragged out their scheduling decisions.
Tech site Venturebeat, citing anonymous sources, says doctors are too overwhelmed and weary to evaluate how many steps you took this weekend.
GlaxoSmithKline, Actelion, Sanofi and Roche are said to be among a host of suitors.
These healthcare plans allow employees and employers to avoid ACA penalties but provide little coverage.
The regulator and patients will chat for two days in October.
A study indicates consumers stop using them at the six-month mark.
CureDuchenne is giving biotech Prosena $7 million to help its Duchenne Muscular Dystrophy treatment move along.
Cologuard was the first approved fecal-based screening test for the disease, and it was also the first product the FDA and CMS approved on the very same day through the so-called Parallel Review program.
Layoffs are reported to be in the offing.
The regulator has already issued more recalls in the first half of 2014 than it has over the past nine years.
The generic ED pills sell for five cents less than Pfizer's branded blue pill, but the undercutting is a bit deeper.
The new rules are expected to do away with the haphazard nature of facility inspections.
Hires and promotions for manufacturers and agencies
The Scottish Medicines Consortium gave a thumb's down to GSK's drug and a Boehringer COPD drug.
A greenlight could garner Pfizer $1B in sales.
A group of investors has drawn up a list of business principles which includes not disparaging biosimilars as being inferior to branded biologics.
The experimental drug is being reviewed for patients with intermediate or high-risk myelofibrosis.
Three House democrats are asking the FDA to get the chemical out of US drugs ASAP.
Medibid users auction up care in exchange for a low price.
The FDA issued a Warning Letter over unapproved drug claims published in Spanish.
Health insurer WellPoint found patients chose lower-priced MRIs when shown how much locations charged for the very same procedure, but the motivation is murky.
The Illinois company says it is keeping the US as its home base, which means no inversion benefit.
Soonish would be good, since a Novartis subsidiary filed a biosimilar with the FDA last month.
The drugmaker is asking the FDA to approve the drug for polycythemia vera patients.
The decades-old drug is winning prescriptions through marketing, but has a free-pass when it comes to clinical trial data.
The latest additions and promotions from the industry.
The pharma payment verification site has been temporarily shut down by CMS due to incorrect information, ProPublica reported today.
The PBM dropped 25 more drugs from its formulary.
Novartis is apologizing to Japan after the Ministry of Health, Labor and Welfare said the company had dragged its feet reporting adverse events for two of its cancer drugs.
The company is calling the move a withdrawal, as opposed to a recall.
The meningitis and encephalitis medications earned a combined $300 million last year.
The cost of fixing healthcare.gov is hovering at around $1 billion, up from the $677-million figure quoted in December
The Wall Street Journal reports that patients are sharing a plethora of information about their clinical trial experiences, from how to get picked, to how to figure out who is in a control group.
Stand Up To Cancer is kicking off a PSA that features Grammy-winner Jennifer Hudson and a Genentech scientist.
The Senate Judiciary Committee's antitrust panel is looking into how three major pharmaceutical manufacturers decided to set minimum prices for their contact lenses.
The American Academy of Pediatricians says an AstraZeneca drug for preemies should be used less often, and the drugmaker is fighting back with an ad campaign that says the new guidelines put too many at risk.
Generics made up almost 75% of prescriptions in the United Kingdom last year.
The company refutes a Financial Times rumor that one was happening soonish.
A study indicates they may do little to reduce the risk of stroke or heart attack.
The FDA slapped a Breakthrough Therapy label on the CLL indication pursuit in February.
The FDA's Center for Drug Evaluation and Research's Office of Communications wants a system that will help assess its messaging reach across the interwebs and its many forums.
The company plans to spin off its pharmaceutical unit.
AstraZeneca's hope is that the blood test could replace tissue samples and be used to identify patients who could benefit from its lung drugs.
A National Institutes of Health-funded study of over 18,000 patients has identified six new genetic risk factors associated with Parkinson's Disease.
The drug did not hit its Phase III primary target of improving progression-free survival.
The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.
Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.
Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.
The Wall Street Journal reports that 44% of dermatologists and plastic surgeons polled in a Sanford Bernstein survey said they would consider Botox alternatives if Allergan becomes a Valeant subsidiary.
AstraZeneca, GlaxoSmithKline, Takeda, Pfizer and Eli Lilly are among seven drugmakers making their discarded molecules available in what amounts to a molecule library.
ProPublica reports that doctors are struggling with a time-intensive registration process and are getting an error message that CMS says is not an error message.
The FDA greenlighted the drug for three cancers.
A $225-million deal with US biotech ArmaGen gives Shire worldwide commercialization rights to an experimental enzyme replacement therapy.
It's the second for this cancer drug in two weeks.
The lawsuit has been wending its way through the courts for a while, and, although it is being deliberated in several other venues, the decision is part of a legal dispute that puts patients in the 36 states offering federal exchanges in limbo.
The Food and Drug Administration has been intent on elevating and reorganizing its office of Generic Drugs since 2012.
HPV testing provides an edge over Pap screenings when it comes to detecting cervical cancer risk.
NPR reports that the move has made Sierra Sandison a type 1 diabetes hero and that users have given the Facebook photo over 4,000 "likes."
CEO Severin Schwan tells Reuters that the Swiss firm will be looking for small acquisitions and partnerships.
AbbVie, in the latest example of a US drugmaker seeking to lower its tax rate, said today that it's buying Dublin-based Shire for $54 billion.
Dr. Joep Lange was en route to the International AIDS Conference in Melbourne, Australia.
He started the Dose of Digital blog in 2008, then left healthcare. Now, after more than two years away, Jonathan Richman says he's back in the business.
Haymarket Media launched the site PsychiatryAdvisor.com today.
The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.